Healthcare provider profile · identity verified

Jon D Misch, D.O.

Allopathic & Osteopathic Physicians|Family Medicine · CEDAR LAKE, IN · NPI 1790767465

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Jon D Misch, D.O. received $19.11 in general payments during 2025 across 1 reported records.

Novo Nordisk Inc accounted for 100.0% of that reported general-payment amount.

Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Ozempic by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$19.11

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Novo Nordisk Inc	Unresolved — no canonical attribution shown	$19.11	100.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$19.11	1

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Payment records were found, but the reported records did not identify a specific associated product for this analysis.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Novo Nordisk Inc Exact reporting entity; no affiliate inference	2025	Ozempic open payments reported associated product	CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076	Ozempic · 2024 Exact normalized brand match · 1 Part D row	116	27

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	634	191
Levothyroxine Sodium	Levothyroxine Sodium	465	120
Metformin Hcl	Metformin Hcl	372	99
Losartan Potassium	Losartan Potassium	353	111
Rosuvastatin Calcium	Rosuvastatin Calcium	352	106
Amlodipine Besylate	Amlodipine Besylate	350	111
Lisinopril	Lisinopril	318	96
Metoprolol Succinate	Metoprolol Succinate	278	79
Omeprazole	Omeprazole	266	85
Pantoprazole Sodium	Pantoprazole Sodium	231	71
Tamsulosin Hcl	Tamsulosin Hcl	225	68
Furosemide	Furosemide	220	73
Hydrochlorothiazide	Hydrochlorothiazide	215	67
Metoprolol Tartrate	Metoprolol Tartrate	178	59
Alprazolam	Alprazolam	171	47
Montelukast Sodium	Montelukast Sodium	154	43
Simvastatin	Simvastatin	145	42
Allopurinol	Allopurinol	136	40
Escitalopram Oxalate	Escitalopram Oxalate	132	35
Ozempic	Semaglutide	116	27
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	115	16
Carvedilol	Carvedilol	114	35
Sertraline Hcl	Sertraline Hcl	109	35
Clopidogrel	Clopidogrel Bisulfate	107	33
Trazodone Hcl	Trazodone Hcl	105	28
Gabapentin	Gabapentin	103	36
Pravastatin Sodium	Pravastatin Sodium	98	31
Albuterol Sulfate Hfa	Albuterol Sulfate	96	37
Finasteride	Finasteride	88	29
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	88	25
Ezetimibe	Ezetimibe	82	25
Famotidine	Famotidine	76	23
Warfarin Sodium	Warfarin Sodium	75	16
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	72	22
Metformin Hcl Er	Metformin Hcl	68	19
Duloxetine Hcl	Duloxetine Hcl	67	19
Fluticasone Propionate	Fluticasone Propionate	66	22
Tramadol Hcl	Tramadol Hcl	60	17
Alendronate Sodium	Alendronate Sodium	57	15
Ropinirole Hcl	Ropinirole Hcl	54	12
Clonazepam	Clonazepam	52	11
Lovastatin	Lovastatin	52	17
Amiloride-Hydrochlorothiazide	Amiloride/Hydrochlorothiazide	51	16
Isosorbide Mononitrate Er	Isosorbide Mononitrate	47	14
Zolpidem Tartrate	Zolpidem Tartrate	47	suppressed
Irbesartan	Irbesartan	46	14
Potassium Chloride	Potassium Chloride	46	20
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	42	37
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	42	14
Meclizine Hcl	Meclizine Hcl	41	15
Pioglitazone Hcl	Pioglitazone Hcl	40	15
Citalopram Hbr	Citalopram Hydrobromide	39	suppressed
Synthroid	Levothyroxine Sodium	39	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	38	11
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	37	14
Prednisone	Prednisone	36	18
Triamcinolone Acetonide	Triamcinolone Acetonide	36	22
Glimepiride	Glimepiride	34	11
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	34	suppressed
Glipizide	Glipizide	33	11
Nitroglycerin	Nitroglycerin	32	17
Spironolactone	Spironolactone	32	suppressed
Benazepril Hcl	Benazepril Hcl	31	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	30	suppressed
Meloxicam	Meloxicam	30	11
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	28	16
Fluoxetine Hcl	Fluoxetine Hcl	27	suppressed
Donepezil Hcl	Donepezil Hcl	26	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	26	suppressed
Valsartan	Valsartan	26	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	26	suppressed
Mounjaro	Tirzepatide	25	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	24	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	24	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	24	suppressed
Jardiance	Empagliflozin	24	suppressed
Pregabalin	Pregabalin	24	suppressed
Diclofenac Sodium	Diclofenac Sodium	23	suppressed
Eliquis	Apixaban	23	suppressed
Eszopiclone	Eszopiclone	23	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	23	suppressed
Ramipril	Ramipril	23	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	22	suppressed
Terazosin Hcl	Terazosin Hcl	22	suppressed
Baclofen	Baclofen	21	suppressed
Diazepam	Diazepam	21	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	21	15
Breo Ellipta	Fluticasone/Vilanterol	19	suppressed
Xarelto	Rivaroxaban	19	suppressed
Clonidine Hcl	Clonidine Hcl	18	suppressed
Fenofibrate	Fenofibrate	18	suppressed
Mirtazapine	Mirtazapine	18	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	17	suppressed
Cyanocobalamin Injection	Cyanocobalamin (Vitamin B-12)	17	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	17	suppressed
Enalapril Maleate	Enalapril Maleate	17	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	16	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	16	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	16	suppressed
Propranolol Hcl	Propranolol Hcl	16	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	16	11
Azelastine Hcl	Azelastine Hcl	15	suppressed
Bupropion Xl	Bupropion Hcl	15	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	15	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Lorazepam	Lorazepam	15	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	15	suppressed
Fluconazole	Fluconazole	14	suppressed
Hydralazine Hcl	Hydralazine Hcl	14	suppressed
Rivastigmine	Rivastigmine Tartrate	14	suppressed
Atenolol	Atenolol	13	suppressed
Lansoprazole	Lansoprazole	13	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	13	suppressed
Spiriva Respimat	Tiotropium Bromide	13	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	13	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	12	suppressed
Aripiprazole	Aripiprazole	12	suppressed
Azithromycin	Azithromycin	12	11
Klor-Con M20	Potassium Chloride	12	suppressed
Ventolin Hfa	Albuterol Sulfate	12	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	11	suppressed
Celecoxib	Celecoxib	11	suppressed
Humulin 70/30 Kwikpen	Insulin Nph Hum/Reg Insulin Hm	11	suppressed
Klor-Con M10	Potassium Chloride	11	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	11	suppressed
Sucralfate	Sucralfate	11	suppressed
Telmisartan	Telmisartan	11	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	11	suppressed
Tresiba Flextouch U-100	Insulin Degludec	11	suppressed
Trulicity	Dulaglutide	11	suppressed
Vyvanse	Lisdexamfetamine Dimesylate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$19.11 · 1 records	Novo Nordisk Inc	—	1	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error